Francis Richard D, President and CEO of Teva Pharmaceutical Industries (TEVA), has demonstrated a consistent pattern of selling company stock over the past two years, with no recorded purchases in the same period. According to SEC Form 4 filings, his 29 reported transactions since 2024 have all been sales, totaling over $34.6 million in aggregate value. The most significant disposals occurred in early 2026, including a $13.3 million sale on March 3 and two transactions on February 15 worth $9.79 million and $5.53 million. These large-scale disposals followed earlier, smaller sales in 2025, such as a $1.28 million transaction on February 18 and multiple six-figure sales throughout March of that year.
The transactions appear to follow a structured approach, with sales often clustered within short timeframes—particularly in early March across multiple years. While some filings include awards (coded "A") and option exercises (coded "M"), these do not represent open-market purchases. The absence of any buy transactions suggests a one-directional disposition of holdings in TEVA. The recent acceleration in both volume and value of sales—with 11 disposals in 2026 alone—indicates an ongoing reduction in Francis's stake in the company. The filings do not disclose whether these sales represent planned divestments or other financial strategies, but the pattern underscores a clear trend toward decreasing equity exposure in Teva.
AI-assisted summary